Matt D. Galsky

Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer

Guru Sonpavde, John M. Burke, J. R. Caton et al. · Annals of Oncology · 2011 · 141 citations

First-line Therapy, Urology, Phase Ii Trial +9

Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650).

Padmanee Sharma, Russell K. Pachynski, Vivek Narayan et al. · Journal of Clinical Oncology · 2019 · 91 citations

Cancer Management, Immunology, Phase Ii Study +17

ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer

Guru Sonpavde, Andrea Necchi, Shilpa Gupta et al. · Future Oncology · 2019 · 90 citations · Full text

Primary analysis from DS8201-A-U105: A phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC).

Matt D. Galsky, Gianluca Del Conte, Silvia Foti et al. · Journal of Clinical Oncology · 2022 · 85 citations

Immunology, Immunoediting, Pathology +17

Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): Results from a phase I/II study.

Scott T. Tagawa, Bishoy M. Faltas, Elaine T. Lam et al. · Journal of Clinical Oncology · 2019 · 84 citations

Phase I/ii Study, Immunology, Immunoediting +20